Stewart T A, Nolan T M, Hogg G, McEwen J
Clinical Epidemiology and Biostatistics Unit, University of Melbourne, Department of Paediatrics, Victoria, Australia.
J Paediatr Child Health. 1996 Oct;32(5):378-81. doi: 10.1111/j.1440-1754.1996.tb00933.x.
To determine antibody levels to the Australian manufactured combined diphtheria, tetanus and pertussis (DTP) vaccine (Triple Antigen, CSL Ltd) in infants before and after their primary immunization course.
Serosurvey (antibody prevalence study) in two groups: infants aged 5-9 weeks who had not received any immunizations (n = 25), and infants aged 7-10 months who had received two (n = 25) or three immunizations (n = 57) with DTP, sampled from infants attending the Royal Children's Hospital, Melbourne, either as inpatients or outpatients between February and April 1993. The immunization history for each infant was determined from hospital records, the parent-held child health record, or the local council or family doctor who immunized the infant.
Enzyme immunoassay (EIA) of antibodies to diphtheria and tetanus showed all infants to have adequate protective levels after two or three vaccinations (> or = 0.01 IU/mL). All subjects who had received all three DTP vaccinations had detectable antibody to at least one pertussis antigen. Antibodies to the pertussis antigens filamentous haemagglutinin and pertussigen (pertussis toxin) were comparable to levels determined for whole cell pertussis vaccines used elsewhere in the world. EIA-determined antibodies to pertussis agglutinogen type 2 and agglutinogen type 3 showed substantially higher geometric mean titres when results for pre-immunization and post-immunization subjects were compared.
These data show that the Australian manufactured DTP vaccine has immunogenic properties similar to those of vaccines used elsewhere, and that antibody concentrations following immunization are at levels consistent with efficacy.
测定澳大利亚生产的白喉、破伤风和百日咳联合疫苗（三联疫苗，CSL有限公司）在婴儿初次免疫疗程前后的抗体水平。
对两组婴儿进行血清学调查（抗体患病率研究）：5 - 9周龄未接受任何免疫接种的婴儿（n = 25），以及7 - 10月龄已接种两剂（n = 25）或三剂（n = 57）三联疫苗的婴儿，这些婴儿于1993年2月至4月期间从墨尔本皇家儿童医院的住院或门诊患儿中抽取。通过医院记录、家长持有的儿童健康记录或为婴儿实施免疫接种的地方议会或家庭医生确定每个婴儿的免疫接种史。
对白喉和破伤风抗体的酶免疫测定（EIA）显示，所有婴儿在接种两剂或三剂疫苗后均具有足够的保护水平（≥0.01 IU/mL）。所有接种了三剂三联疫苗的受试者均检测到至少一种百日咳抗原的抗体。针对百日咳抗原丝状血凝素和百日咳毒素（百日咳杆菌毒素）的抗体水平与世界其他地方使用的全细胞百日咳疫苗所测定的水平相当。比较免疫前和免疫后受试者的结果时，EIA测定的针对2型百日咳凝集原和3型凝集原的抗体显示出显著更高的几何平均滴度。
这些数据表明，澳大利亚生产的三联疫苗具有与其他地方使用的疫苗相似的免疫原性，并且免疫接种后的抗体浓度处于与疗效一致的水平。
